Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

Presenter: Michael J. Reardon, Didier Tchetche, Alexandra J. Lansky

October 31, 2017

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

News Daily News

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Caitlin E. Cox

September 29, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Presentation SWVS 2017

Cases: The Good, The Bad and The Ugly

Presenter: Michael J. Reardon

May 07, 2017

Presentation SWVS 2017

Extreme Sizing: The Very Small and the Very Large

Presenter: Michael J. Reardon

May 06, 2017

Presentation SWVS 2017

TAVR: Evolving Risk Assessment and Expectations

Presenter: Michael J. Reardon

May 06, 2017

Presentation SWVS 2017

Heart Valve Dysfunction With ESRD: Options and Expectations

Presenter: Michael J. Reardon

May 06, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Presentation SIF 2017

Bicuspid Valve Disease

Presenter: Michael J. Reardon

March 11, 2017

Presentation SIF 2017

Not So Fast: SAVR Will Win

Presenter: Michael J. Reardon

March 11, 2017

Presentation SIF 2017

Bicuspid Aortic Valve Disease and TAVR

Presenter: Michael J. Reardon

March 11, 2017

CME

TAVR Evolves: Are You and the Heart Team Ready?

CME

Advertisement

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Point A Multi-Device Lesion-Specific Approach is Preferred!

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Cases: The Good, The Bad and The Ugly

Extreme Sizing: The Very Small and the Very Large

TAVR: Evolving Risk Assessment and Expectations

Heart Valve Dysfunction With ESRD: Options and Expectations

First Results from the SURTAVI Clinical Trial

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Bicuspid Valve Disease

Not So Fast: SAVR Will Win

Bicuspid Aortic Valve Disease and TAVR

TAVR Evolves: Are You and the Heart Team Ready?

Evolving Thresholds for TAVR - Moving Down the Risk Spectrum

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content